T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016

T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016
Published Jun 28, 2016
53 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016, provides in depth analysis on T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted pipeline therapeutics.

The report provides comprehensive information on the T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e)
- The report reviews T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted therapeutics and enlists all their major and minor projects
- The report assesses T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) targeted therapeutics

Reasons to buy

- Gain strategically significant competit

  
Source:
Document ID
GMDHC0060TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Overview71
Therapeutics Development83
  T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Stage of Development81
  T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Therapy Area91
  T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Indication101
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Companies132
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Products under Development by Universities/Institutes152
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type211
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Companies Involved in Therapeutics Development225
  Amgen Inc.221
  GlaxoSmithKline Plc231
  MacroGenics, Inc.241
  Tiziana Life Sciences Plc251
  Xencor, Inc.261
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Drug Profiles2711
  foralumab Drug Profile271
  Monoclonal Antibodies to Activate CD3 and CD16 and to Inhibit HBsAg for HBV Infection and Oncology Drug Profile281
  otelixizumab Drug Profile292
  teplizumab Drug Profile312
  XENP-1138 Drug Profile331
  XmAb-13551 Drug Profile341
  XmAb-13677 Drug Profile352
  XmAb-14045 Drug Profile371
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Dormant Projects381
T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) Featured News &Press Releases3913
  May 19, 2016: Immunotherapy Journal Review of Anti - CD3 Monoclonal Antibodies Highlights Therapeutic Potential of Tizianas Foralumab391
  Jan 11, 2016: Tiziana announces plans for clinical development of foralumab, the company fully human CD3 antibody391
  Nov 06, 2014: Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting401
  Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet411
  Jun 23, 2011: MacroGenics To Present Protege Phase III Clinical Data Of Teplizumab In Type 1 Diabetes At ADA In San Diego, US421
  Mar 11, 2011: Tolerx And GSK Announce Phase III Defend-1 Study Of Otelixizumab In Type 1 Diabetes Fails Primary Endpoint421
  Oct 20, 2010: MacroGenics And Lilly Report Pivotal Clinical Trial Of Teplizumab Did Not Meet Primary Efficacy Endpoint431
  Sep 23, 2010: Tolerx Enrolls First Patient In Europe In DEFEND-2 Phase III Clinical Study For Treatment Of Type 1 Diabetes441
  Sep 23, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study At European Association For Study Of Diabetes Annual Meeting451
  Jun 28, 2010: Tolerx Initiates Confirmatory Phase III Trial With Otelixizumab For Type 1 Diabetes461
  Jun 28, 2010: Tolerx Presents Baseline Data From DEFEND-1 Study Validating C-Peptide As Critical Clinical Measure For New-Onset Type 1 Diabetes461
  Mar 17, 2010: Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation Of Beta Cell Function471
  Jan 07, 2010: Tolerx Completes Patient Enrollment For DEFEND-1 Phase 3 Clinical Study Of Otelixizumab, For The Treatment Of Type 1 Diabetes481
  Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data At The IDF's 20TH World Diabetes Congress491
  Oct 21, 2009: Tolerx Presents Otelixizumab Phase II Dose Optimization Data At The IDF s 20TH World Diabetes Congress502
Appendix522
  Methodology521
  Coverage521
  Secondary Research521
  Primary Research521
  Expert Panel Validation521
  Contact Us521
  Disclaimer531

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Surface-Glycoprotein-CD3-Epsilon-Chain-T-Cell-Surface-Antigen-T3-Leu-4-Epsilon-Chain-or-CD3e-Pipeline-Review-H1-2016-2088-16022>
  
APA:
Global Markets Direct - Market Research. (2016). T-Cell Surface Glycoprotein CD3 Epsilon Chain (T-Cell Surface Antigen T3/Leu-4 Epsilon Chain or CD3e) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Surface-Glycoprotein-CD3-Epsilon-Chain-T-Cell-Surface-Antigen-T3-Leu-4-Epsilon-Chain-or-CD3e-Pipeline-Review-H1-2016-2088-16022>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.